Impact of a pharmacist driven anticoagulation reversal program at a large academic medical center.

Autor: Procopio GL; Department of Pharmacy, Hackensack University Medical Center, 30 Prospect Ave, Hackensack, NJ, 07601, USA. Gabrielle.Procopio@gmail.com.; Department of Emergency Medicine, Hackensack Meridian School of Medicine, Nutley, NJ, 07110, USA. Gabrielle.Procopio@gmail.com., Jain RP; Department of Pharmacy, Hackensack University Medical Center, 30 Prospect Ave, Hackensack, NJ, 07601, USA., Tompkins DM; Department of Pharmacy, Hackensack University Medical Center, 30 Prospect Ave, Hackensack, NJ, 07601, USA.; Department of Pharmacy Practice and Administration, Ernest Mario School of Pharmacy, Rutgers University, The State University of NJ, New Brunswick, NJ, 08854, USA., Perez JM; Department of Surgery, Hackensack University Medical Center, Hackensack, NJ, 07601, USA., Bicking K; Department of Pharmacy, Hackensack University Medical Center, 30 Prospect Ave, Hackensack, NJ, 07601, USA.
Jazyk: angličtina
Zdroj: Journal of thrombosis and thrombolysis [J Thromb Thrombolysis] 2022 Jan; Vol. 53 (1), pp. 158-166. Date of Electronic Publication: 2021 Jun 07.
DOI: 10.1007/s11239-021-02491-7
Abstrakt: In major/life-threatening bleeding, administration of timely and appropriate reversal agents is imperative to reduce morbidity and mortality. Due to complexities associated with the use of reversal agents, a clinical pharmacist-driven anticoagulation reversal program (ARP) was developed. The goal of this program was to ensure appropriateness of reversal agents based on the clinical scenario, optimize selection and avoid unintended consequences. This study describes the impact of a pharmacist-driven anticoagulation program on patient outcomes and cost. A single center retrospective chart review of adult patients whom the ARP was consulted from October 2018 to January 2020 was performed. Patients were included in the efficacy analysis if they were > 18 years of age and presented with acute bleeding. Patients were excluded from the efficacy analysis if the recommended reversal agent was not administered, if a repeat head CT was not available for patients who presented with intracranial hemorrhage (ICH), or if the patient was not bleeding. All patients were included in the economic evaluation. The primary outcome was the percentage of patients who achieved effective hemostasis within 24 h of anticoagulation reversal. Secondary outcomes include incidence of thromboembolic events, in-hospital mortality, and cost avoidance. One hundred twenty-one patients were evaluated by the ARP with 92 patients included in the efficacy analysis. The primary sites of bleeding were ICH in 46% and gastrointestinal (GI) in 29%. Hemostasis was achieved in 84% of patients. Thrombotic events occurred in 7.4% of patients and in-hospital mortality was 26.4%. Total cost avoidance was $1,005,871.78. To our knowledge, this is the first study to evaluate the impact of a pharmacist-driven ARP on clinical and economic outcomes. Implementation of a pharmacist-driven ARP was associated with favorable outcomes and cost savings.
(© 2021. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.)
Databáze: MEDLINE
Externí odkaz: